
Opinion|Videos|July 5, 2024
Key Efficacy Data from PERSEUS in Newly Diagnosed Multiple Myeloma
Author(s)Cesar Rodriguez, MD, Frits van Rhee, MD, PhD
Myeloma specialists provide comprehensive insights on key data from the PERSEUS trial evaluating MRD status in patients receiving DARA-VRd and VRd.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What are your initial impressions of the efficacy data from PERSEUS?
- What are the potential clinical implications of this data in your practice for TE NDMM patients?
- How might this data impact the current treatment landscape?
Advertisement
Related to this article

In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Advertisement
Advertisement
Trending on CancerNetwork
1
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
2
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
3
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
4
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
5


